Company Interview / Argenica Therapeutics (ASX:AGN) Investor Presentation

Argenica Therapeutics (ASX: AGN) is undertaking the development and commercialisation of a novel drug based on the pioneering work of Professor Bruno Meloni and Clinical Professor Neville Knuckey at the University of Western Australia (UWA) and the Perron Institute for Neurological and Translational Science (Perron Institute). The drug, known as ARG-007, a cationic, arginine rich peptide, has neuroprotective properties that has the potential to offer protection to the brain following stroke and other acute central nervous system injuries.

In June 2021, Aregnica Therapeutics listed on the ASX, raising the necessary funds to allow Argenica to develop a best in class neuroprotective therapeutic. The Company has since completed a Phase 1 clinical trial proving the safety and tolerability of ARG-007 in healthy human volunteers and will shortly commence dosing acute ischaemic stroke patients in a Phase 2 clinical trial in Australia.

Aregnica Therapeutics CEO Dr Liz Dallimore explains the company's progress, plans for commercialisation and partnerships.

*The information contained in this event is general in nature and is not intended as advice. Before acting on information you've seen or heard at this event, you should seek professional financial advice which takes into account your personal circumstances.

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD